PGNX News and Press, Progenics Pharmaceuticals Inc. From 06/13/19

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, is mailing a lette...

The first patient has been dosed in a Phase 2 clinical trial, ARROW , evaluating Progenics Pharmaceuticals' (NASDAQ: PGNX ) I-131 1095 radiotherapy, combined with Pfizer (NYSE: PFE ) and Astellas' ( OTCPK:ALPMY )  XTANDI (enzalutamide), for the treatment of metastatic castration-res...

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the first patient has been dosed in the Company’s...

Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more ...

I discovered CytoDyn (CYDY) when performing research for an article on Progenics Pharmaceuticals (PGNX). As I was reading through PGNX SEC filings, I saw a few references to Leronlimab (PRO 140) , a fully humanized monoclonal antibody treatment for HIV that CytoDyn acquired from Progenics b...

ALPHARETTA, Ga. , June 11, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics")(NASDAQ: PGNX), announced today that it has delivered a letter t...

NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced today announced that six abstracts highlighting AZEDRA (ioben...

ALPHARETTA, Ga. , June 4, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), today issued the following ...

  - Long-Term Follow Up Data from Pivotal Study Presented at ASCO - - Patients Treated with AZEDRA Show Overall Survival of 73.1% at Two Years and 44.2% at Four Years - NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company d...

Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company de...